Please ensure Javascript is enabled for purposes of website accessibility

Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR Therapeutics

By Keith Speights and Brian Orelli, PhD – Sep 4, 2021 at 7:55AM

Key Points

  • Arbor Biotechnologies recently announced an expanded collaboration with Vertex to develop CRISPR gene-editing therapies.
  • The deal is worth up to $1.2 billion, but the amount of any up-front payment from Vertex wasn't revealed.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vertex plans to work more closely on CRISPR gene editing with a small privately-held biotech.

Vertex Pharmaceuticals (VRTX -1.01%) has worked closely with CRISPR Therapeutics (CRSP -0.07%) for quite a while to develop a CRISPR gene-editing therapy targeting rare blood diseases. Recently, Vertex expanded a partnership focused on CRISPR gene editing, but it's not with CRISPR Therapeutics. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Vertex is expanding its collaboration with Arbor Biotechnologies.

10 stocks we like better than Vertex Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 9, 2021


Keith Speights: Vertex Pharmaceuticals, the ticker there is VRTX, is expanding a partnership with a smaller biotech that's focused on CRISPR gene editing. But we're not talking about CRISPR Therapeutics in this case.

Yes, Vertex is a partner with CRISPR Therapeutics. They've worked together for several years. They have a very promising CRISPR gene editing therapy. But in this case, Vertex is making a move with a small privately held company called Arbor Biotechnologies. So Brian, what's behind Vertex's expanded collaboration with Arbor?

Brian Orelli: Yeah, Arbor is using gene editing to make ex vivo engineered cell therapies, so you pull cells out of the patient, manipulate their cells and then put them back into the patient. The deal covers seven different areas of focus.

They disclosed a couple of them. So there's insulin-producing hyperimmune isolate cells. They want to use those for the treatment of Type 1 diabetes and then they are doing, and I'm quoting next-generation approaches in sickle cell disease and beta-thalassemia. I'm sure CRISPR Therapeutics was not happy to hear about that since both those indications are their lead indication for their lead treatment, and then there's the other undisclosed diseases, up to seven different programs.

Vertex's paying an undisclosed up-front payments, and then they're paying up to $1.2 billion in milestones. Although some of those are regulatory and commercial milestones so those obviously wouldn't get paid until it was clear that the drugs were working.

Speights: Yeah interestingly, in this case, the press release only came from Arbor Biotechnologies. Vertex didn't have anything on its website about this deal.

I'm not sure if Vertex was intentionally trying to downplay it because of the relationship with CRISPR Therapeutics or if this was just obviously this is a bigger deal for Arbor. It makes sense that they would be trying to get this word out and maybe that the financial terms, as you said, there up to $1.2 billion in milestones, maybe that it wasn't a really large up-front amount here.

Orelli: Yeah, I'm sure it's not material to Vertex's financial situation in the near term, or even medium term.

Speights: Yeah, I think you're Vertex shareholder, right, Brian?

Orelli: Yeah.

Speights: Yeah, I am too. I like Vertex doing deals like this. I don't have a problem with them looking outside of the partnership with CRISPR Therapeutics to look at other gene-editing technology and other approaches, other candidates.

Orelli: They have cystic fibrosis that could potentially put all their whole franchise of drugs out of business if it worked better, so they're always constantly trying to improve.

Speights: Yeah, and Vertex is another company with a hefty cash stockpile and, hey, put that money to use.

Keith Speights own shares of Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
$312.98 (-1.01%) $-3.18
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$54.99 (-0.07%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.